Research programme: cysteinyl leukotriene receptor 1/2 inhibitors - Ono PharmaceuticalAlternative Names: ONO-RS-531
Latest Information Update: 25 May 2010
At a glance
- Originator Ono Pharmaceutical
- Mechanism of Action Leukotriene receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 25 Oct 2005 Preclinical trials in Asthma in Japan (unspecified route)